Age-dependent Bupivacaine-induced Muscle Toxicity during Continuous Peripheral Nerve Block in Rats
Nouette-Gaulain, Karine M.D., Ph.D.*; Dadure, Christophe M.D., M.Sc.†; Morau, Didier M.D., M.Sc.†; Pertuiset, Claire Ph.D.‡; Galbes, Olivier Ph.D.§; Hayot, Maurice∥; Mercier, Jacques M.D., Ph.D.#; Sztark, François M.D., Ph.D.**; Rossignol, Rodrigue Ph.D.††; Capdevila, Xavier M.D., Ph.D.‡‡
Background: Regional blocks improve postoperative analgesia and postoperative rehabilitation in children and adult patients. Continuous peripheral nerve blocks have been proposed as safe and effective techniques for postoperative pain relief and chronic pain therapy, particularly in small children. Few clinical reports have described myotoxicity induced by bupivacaine in these young patients, in contrast with a larger number of observations in adults. Here, the authors addressed this issue by a comparative evaluation of bupivacaine-induced myotoxicity in young versus adult rats.
Methods: Femoral nerve block catheters were inserted in male Wistar rats. Young (3-week-old) and adult (12-week-old) rats were randomly assigned to received seven injections (1 ml/kg) of 0.25% bupivacaine (n = 6 per experiment) or isotonic saline (n = 6 per experiment) at 8-h intervals. Rats were killed 8 h after the last injection. Psoas muscle adjacent to the femoral nerve was quickly dissected. Oxygen consumption rates were measured in saponin-skinned fibers, mitochondrial adenosine triphosphate synthesis rates were determined by bioluminescence, and citrate synthase activity was determined by spectrophotometry. Muscle ultrastructural damage was also examined and scored as normal, focal disruption, moderate disruption, or extreme disruption of the sarcomeres.
Results: Bupivacaine caused a reduction of mitochondrial adenosine triphosphate synthesis rate, a decrease of citrate synthase activity, and muscle ultrastructural damages. Young rats treated with bupivacaine showed more severe alterations of mitochondrial bioenergetics and muscle ultrastructure.
Conclusions: These findings demonstrate that bupivacaine-induced myotoxicity can be explained by mitochondrial bioenergetics alterations, which are more severe in young rats.
REGIONAL blocks improve postoperative analgesia and postoperative rehabilitation in children and in adult patients. Continuous peripheral nerve blocks have been proposed as safe and effective techniques for postoperative pain relief and chronic pain therapy, particularly in small children.1–5
The local anesthetic solution during continuous blocks comes into contact with muscles. After ilioinguinal and iliohypogastric nerve block, the local anesthetic solution is often located in the abdominal muscles, rather than in the vicinity of the nerves between the muscle layers, as shown under direct ultrasonographic control.6
Therefore, local anesthetic obviously spreads through muscle in continuous peripheral nerve blocks. Bupivacaine-induced myotoxicity is now well described in adult patients, and ongoing investigations are performed to understand the molecular mechanisms of this toxicity, along with the search for protective approaches. It was recently suggested that the local toxicity of bupivacaine in children may create a greater risk, but not many data are available on this subject.7,8
The published case reports of bupivacaine-induced myotoxicity typically regard adult patients, scheduled to undergo cataract surgery with retrobulbar anesthesia,9
a technique not routinely used in children. Moreover, the use of peripheral nerve catheter in children is a new technique that will increase in the coming years.1,2,10–12
In addition, most of the laboratory investigations of drug-induced myotoxicity are performed in the muscle of adult rats, and no data are available in young rats.
This raises the fundamental question of bupivacaine variable toxicity with respect to age. Are young individuals more protected against bupivacaine-induced toxicity, because of possible differences in energy metabolism and physiology, or can it be simply explained by the lack of studies and case investigations in young subjects?
Given the significance of the bupivacaine toxicity in adult patient muscle, it is requisite to evaluate this phenomenon in the young. Previous analyses of bupivacaine toxicity revealed a key role of mitochondria with a series of bioenergetic alterations, which were described on different experimental models, ranging from isolated rat mitochondria to human myocytes in culture. Recently, using a protocol of anesthesia similar to those currently being developed in clinical practice, we observed that bupivacaine iterative injections led to a large reduction of the muscle oxidative capacity, along with the emergence of severe ultrastructural organelle and tissue damage, including mitochondrial cristolysis and autophagy.13,14
However, a comparison of the different studies, which investigated the mechanisms of bupivacaine myotoxicity on different models and using different protocols, indicates various effects that might coexist in situ
and act synergistically or sequentially. They include (1) the specific inhibition of mitochondrial respiratory chain complex I (as observed on isolated mitochondria), (2) oxidative phosphorylation (OXPHOS) uncoupling, (3) the specific inhibition of the mitochondrial adenosine triphosphate (ATP) synthase, (4) the decrease of mitochondrial membrane electric potential, (5) the fragmentation of the mitochondrial network, and (6) the possible onset of mitoptosis.14–16
Therefore, at high concentrations, bupivacaine can be considered a potent mitochondrial inhibitor, and as such, differences in mitochondrial composition or respiratory steady state could explain the differences in sensitivity to bupivacaine observed in patients.17
It was demonstrated in previous biochemical studies that mitochondrial OXPHOS inhibitors can produce different effects on ATP synthesis, and subsequent variable clinical manifestations, according to the respiratory steady state under which the inhibition is performed,18
the tissue considered,19
or the individual.17
Moreover, it is typically observed that a biochemical compensation for an OXPHOS inhibition can result from the activation of different mechanisms, such as the attenuation by respiratory chain intermediate substrates,20
or enzyme mobilization.21
In the current study, we hypothesized that bupivacaine-induced myotoxicity, which relies on mitochondrial bioenergetic impairment, could vary in severity among individuals with different energy states. In particular, both the capacity and the reliance on mitochondrial OXPHOS for energy production can decrease with age,22
such that young individuals might be more sensitive to a decline of mitochondrial function induced by bupivacaine. To test this hypothesis, we compared the toxicity of bupivacaine on mitochondrial energy production, in young rats (3 weeks) versus
adults (12 weeks).
Materials and Methods
This study, including care of the animals involved, was conducted according to the official edict presented by the French Ministry of Agriculture (Paris, France), and the recommendations of the Declaration of Helsinki. Thus, these experiments were conducted in an authorized laboratory and under the supervision of an authorized researcher (K.N.-G.).
Plain bupivacaine hydrochloride, 0.25% (7.5 mm), was purchased from Astra Zeneca (Rueil-Malmaison, France) for rat administration. All other reagents were purchased from Sigma-Aldrich (Saint Louis, MO), with the exception of the ATP monitoring kit (ATP Bioluminescence Assay Kit HS II; Roche Diagnostics GmbH, Mannheim, Germany).
Experiments were conducted on young (3-week-old, 70- to 100-g) and adult (12-week-old, 200- to 240-g) male Wistar rats. Rats were housed in a regulated facility with a 12-h light/12-h dark cycle, were fed with chow, and were allowed free access to tap water. After anesthesia with intraperitoneal sodium pentobarbital (40 mg/kg) and subcutaneous injection of lidocaine (3 and 10 mg, respectively, in young and adult rats), a plexus catheter (Pajunk, Geisingen, Germany; 25 gauge, 0.8 mm OD, and 20 gauge, 0.9 mm OD, in young and adult rats, respectively) was surgically inserted under the inguinal ligament near the left femoral nerve sheath by an authorized and trained researcher (K.N.-G.). It was fixed with stitches on the quadriceps muscle, passed under the skin, and exited at the neck. Incisions were subsequently closed by suturing.
Animals were randomly divided into four different groups according to the type of perineural catheter injection of 1 ml/kg bupivacaine, 0.25% (bupivacaine groups), or saline (saline groups) and age (adult and young rats). Seven perineural injections 8 h apart were performed. They induced a decrease in pinprick sensation in the cutaneous distribution of the femoral nerve but not complete motor blockade in the first hour after each bupivacaine injection. Rats were killed by cervical dislocation 8 h after the last perineural injection, when the bupivacaine concentration in muscle was below the detection threshold (< 0.3 μg/g tissue), as previously published.23
Psoas muscle was quickly dissected adjacent to the femoral nerve, with the former tip region of the catheter located in the middle of the tissue block, and placed in a normoxic (i.e.
, equilibrated with air), cooled (4°C) relaxing solution (solution 1: 10 mm EGTA, 3 mm Mg2+
, 20 mm taurine, 0.5 mm dithiothreitol, 5 mm ATP, 15 mm phosphocreatine, 20 mm imidazole, and 0.1 m K+
2-[N-morpholino]ethane sulfonic acid, pH 7.2). To assess mitochondrial respiration, we used a permeabilized muscle fiber technique.24
Bundles of 2- to 5-mg fibers were excised from the surface of the psoas and then permeabilized in solution 1 with 50 μg/ml saponin added. The bundle was then washed twice for 10 min each time in solution 2 (10 mm EGTA, 3 mm Mg2+
, 20 mm taurine, 0.5 mm dithiothreitol, 3 mm phosphate, 1 mg/ml fatty acid–free bovine serum albumin, 20 mm imidazole, and 0.1 m K+
2-[N-morpholino]ethane sulfonic acid, pH 7.2) to remove saponin. All procedures were performed at 4°C with extensive stirring. The success of the permeabilization procedure was estimated by determining the activity of the cytosolic lactate dehydrogenase, and the mitochondrial citrate synthase in the medium. After 15–20 min of permeabilization, more than 60% of the cytosolic lactate dehydrogenase was found in the external medium, and the mitochondrial citrate synthase activity in the medium remained below 5%.24,25
The oxygen consumption rate was measured polarographically at 30°C using a Clark-type electrode (Strathkelvin Instruments, Glasgow, United Kingdom) connected to a personal computer that displayed on-line the respiration rate value (949 Oxygen System; Strathkelvin Instruments). Oxygen solubility in the medium was considered to be equal to 450 nmol O/ml. For each measurement, a 2-ml oxygraph chamber was filled with one bundle of fibers in solution 2 with 10 mm malate plus 10 mm glutamate, 10 mm malate plus 10 mm pyruvate (substrates of complex I), or succinate plus complex I inhibitor rotenone (1 mg/ml dimethyl sulfoxide and ethanol 1:1) as substrates; 50 μm di(adenosine 5′)-pentaphosphate, 20 μm EDTA, and 1 mm iodoacetate were also added to the cuvette to inhibit extramitochondrial ATP synthesis (via
the glycolysis or the adenylate kinase) and ATP hydrolysis.26
After 5 min, adenosine diphosphate was added to a final concentration of 1 mm to initiate state 3 respiration (concomitant with ATP synthesis) under saturating conditions.27
State 4 respiration was recorded after addition of 70 μm atractyloside (adenine nucleotide translocator inhibitor) and 1 μm oligomycin (ATPase inhibitor). After the measurements, fibers were removed, dried on a precision wipe, and weighed. Respiration was expressed as ng atom O · min−1
· mg wet weight−1
of the muscle fiber. Concomitant ATP synthesis measurements were performed by bioluminescence measurements (luciferin–luciferase system) of the ATP produced after addition of 1 mm adenosine diphosphate. At various time intervals after addition of adenosine diphosphate, 10-μl aliquots were withdrawn from the oxygraph chamber, quenched in 100 μl dimethyl sulfoxide, and diluted in 5 ml ice-cold distilled water. Standardization was performed with known quantities of ATP measured under the same conditions. ATP synthesis rate was expressed as nmol ATP · min−1
· mg wet weight−1
of the muscle fiber.26
This allowed for calculation of the efficiency of ATP production (ATP/O ratio).
For the enzymatic measurements, approximately 60 mg of psoas muscle was minced and homogenized with a glass Potter homogenizer, in ice-cold medium (10% wt/vol) containing 225 mm mannitol, 75 mm sucrose, 10 mm Tris-HCl, and 0.10 mm EDTA, pH 7.2. The homogenate was then centrifuged for 20 min at 650 g
. The supernatant was collected, and the protein concentration was determined.28
Enzymatic activity of citrate synthase was assessed using previously described spectrophotometric procedures on a SAFAS UVmc2 (SAFAS, Monaco, France) and was expressed in nanomoles of substrate transformed per minute and per milligram of protein. Citrate synthase activity was measured as described by Srere29
in the presence of 4% Triton (vol/vol) by monitoring at 412 nm wavelength at 30°C the formation of thionitrobenzoate dianion from the reaction of coenzyme A and 5,5′-dithiobis(2-nitrobenzoic acid).
The muscle sample (20–40 mg) was initially fixed with 3.5% solution of glutaraldehyde in 0.1 m phosphate buffer (pH 7.4).30,31
The samples were fixed at 4°C for 24 h until postfixation. The minced tissue samples were postfixed by using 2% osmium tetroxide. After postfixation, the samples were subsequently dehydrated by using a graded series of ethanol washes (30, 50, 75, 95, and 100%). The tissue samples were longitudinally oriented and embedded in epoxy resin (Spurr). Three sample blocks were obtained from each muscle biopsy sample. Thin sections (80–90 nm) were obtained initially and placed on 200-mesh copper grids for electron microscopy. The sections on each grid were stained by using 1.5% uranyl acetate in 70% ethanol, rinsed with distilled water, and then stained with 0.1% lead citrate. Sections were viewed on a Hitachi 7100 electron microscope (Tokyo, Japan) operated at 75 kV in the Centre de Ressources en Microscopie Electronique, Montpellier, France. A representative section on each grid was viewed at ×5,000 magnification, and micrographs were taken of each fiber.
The samples were evaluated by two independent and blind examiners unaware of group or treatment. To access the specific extent of skeletal muscle changes, 100 cross sections per injection site were performed, and 15 cross sections among them were randomly chosen.
Each viable muscle fiber was analyzed for structural muscle damage. Hypercontracted fibers were excluded from the analysis, because the cause of associated damage was unable to be determined.32
A viable muscle fiber was defined as a longitudinally oriented fiber with minimum visible length of 200 μm and minimal muscle contraction. Each fiber was analyzed individually for the extent of damage, and all fibers per subject were assessed for the extent of fiber disruption. The percentage of fibers exhibiting myofibrillar disruption was then calculated for each subject. A disrupted fiber was defined as any fiber containing disruptions in the normal myofibrillar banding pattern. Specifically, any fibers exhibiting Z-line streaming or M-band disruption, as well as disruption of the myofilament structure within sarcomeres, were classified as damaged. An area of disruption occupying one to two adjacent myofibrils and/or one to two continuous sarcomeres was classified as a “focal” disruption.30,31
An area of disruption encompassing 3–10 adjacent myofibrils and/or 3–10 continuous sarcomeres was termed “moderate” disruption, and an area of disruption covering more than 10 adjacent myofibrils and/or continuous sarcomeres was considered “extreme.”
For mitochondrial respiration and citrate synthase activity, quantitative data were reported as a median [25th and 75th percentiles] because of a nonnormal distribution. Data from the four groups was then compared using a Kruskal–Wallis test. Mann–Whitney tests were performed by comparing young saline group versus young bupivacaine group, young saline group versus adult saline group, and young bupivacaine group versus adult bupivacaine group (with P < 0.0166 as significant according to the Bonferroni correction).
Ultrastructural damage in psoas muscle among treatment and age groups was assessed by using the chi-square test, and P values less than 0.05 were considered significant. Agreement between the scorings of the two examiners yielded a Kendall rank correlation coefficient of 0.95 for the microscopic study.
Tests were performed using Sigmastat 3.1 (Systat Software Inc., San Jose, CA).
Rat Analgesia Protocol
Forty-eight rats were included, and no self-mutilation after catheter placement was observed. The catheters were inserted into the perimysium connective tissue, and between muscle fibers without destruction, to reach the vicinity of the femoral nerve where bupivacaine was released. No catheter displacement was observed, and no rat was excluded from the analysis.
Bupivacaine-induced Impairment of Energy Metabolism in Psoas Muscle
Measurements of coupled oxygen consumption rate and the corresponding ATP synthesis were performed in permeabilized fibers using glutamate or pyruvate plus malate, or succinate as substrates (tables 1–3
). In the saline groups, the level of ATP synthesis with the three substrates was significantly higher in young rats than in adult rats. Bupivacaine induced a significant decrease in adenosine diphosphate–stimulated oxygen consumption, along with a significant inhibitory effect on ATP synthesis in both groups. The efficiency of oxidative phosphorylation (ATP/O ratio) was also reduced. No significant difference was observed between the young and the adult rats treated with bupivacaine. In addition, in saline groups, citrate synthase activity was significantly higher in young rats than in adult rats (531 [496–549] and 361 [337–366] ng nmol substrate · min−1
· mg protein−1
, respectively; P
= 0.002, Mann–Whitney post hoc
test). Bupivacaine induced a significant decrease in citrate synthase activity in young rats (440 [428–457] nmol substrate · min−1
· mg protein−1
= 0.002 vs.
saline young rats, Mann–Whitney post hoc
test) and adult rats (278 [269–323] nmol substrate · min−1
· mg protein−1
= 0.009 vs.
saline adult rats, Mann–Whitney post hoc
Bupivacaine-induced Damage in Psoas Muscle Fiber
Electron micrographs of muscle sections taken from adult and young rats were obtained after treatment with saline solution (figs. 1A and B
, respectively) or bupivacaine (figs. 1C and D
). More precisely, muscle damage was primarily absent, focal (1–2 sarcomeres; fig. 1B
), or moderate (3–10 sarcomeres; fig. 1C
) in both young and adults rats in the saline groups. Bupivacaine groups revealed a wide range of abnormalities, ranging from absent to focal, moderate, and extreme (fig. 2
). Extreme muscle damage (> 10 damaged sarcomeres) was seen in bupivacaine groups only (figs. 1D and 2
). Extreme muscle damage was significantly more frequent in the young bupivacaine group than in the adult bupivacaine group (56% vs.
19%, respectively; P
= 0.000016, chi-square test).
Local anesthetics (e.g.
, bupivacaine) are widely used for postoperative regional analgesia in children, even though some studies have clearly demonstrated a potential muscle toxicity risk in adults.9,33,34
Our results show that such a risk is increased in young rats, because we observed more severe alterations in mitochondrial oxidative capacities and a broader alteration of muscle ultrastructure.
First, we observed that the main metabolic fluxes, i.e.
, oxygen consumption rate or ATP synthesis rate, are higher (factor of 2) in young rats as compared with adults, when expressed per mass of tissue. This was explained by a higher content of mitochondria in the young muscle, as evidenced by the corresponding twice higher activity of citrate synthase. Recently, Benard et al.35
evidenced a good correlation between citrate synthase activity and the expression level of respiratory chain complexes I and III, as well as mitochondrial transcription factor A, in five different rat tissues. This suggests that citrate synthase activity could be coordinated with the expression level of respiratory chain complexes and be closely linked to the content of mitochondrial respirasomes. Similar observations were reported in the study of Marcinek et al.
which compared the rate of mitochondrial ATP synthesis and oxygen uptake in 30-day-old and 7-month-old mice, using magnetic resonance spectroscopy. They found a significant increase in ATP synthesis rate in younger muscle. Likewise, the analysis of mitochondrial DNA copy number and cytochrome c
oxidase gene expression in rat and in human skeletal muscle showed a substantial decline with aging.37–39
More precise analysis of human skeletal muscle from individuals of different ages (5 days old and 52 yr old) provided transcriptional evidence for an age-related decline in metabolic capacity, with a decreased expression of the genes encoding proteins involved in mitochondrial bioenergetics, including ATP synthase.39
Therefore, the higher oxidative phosphorylation activity of young rat muscle observed in our study could be due to a higher content of mitochondria (suggested by the significant increase in citrate synthase activity per mass of tissue proteins) and embedded oxidative phosphorylation complexes.
In our study, we also confirmed the inhibitory effect of bupivacaine on mitochondrial respiration and linked-ATP synthesis, as observed in previous work.14
Remarkably, we observed here a greater inhibition of OXPHOS in young rats, with respect to the relative effect of bupivacaine. For example, the rate of mitochondrial ATP synthesis was reduced by 75% in the young rats (using pyruvate–malate as substrates), whereas it was decreased by 55% in the adult rats. This could be explained by the initial difference of the respiratory steady state between adult and young rats, because the metabolic control analysis predicts that the impact of a given inhibition of a mitochondrial enzyme activity on the overall flux of energy production depends on this steady state.18,40
Accordingly, the higher state of ATP production and oxygen consumption measured in young rat muscle suggests that OXPHOS delivers a larger part of muscle energy, so a deficiency of mitochondrial ATP synthesis might lead to more severe consequences. This is in accord with the increased level of muscle ultrastructural alterations observed in young rats.
The mechanisms of bupivacaine-induced myotoxicity might be similar in young and adult individuals, because both can be explained by the impairment of mitochondrial function. In vitro
, it is now well established that bupivacaine uncouples oxidative phosphorylation on isolated mitochondria and further inhibits complex I activity.13,16
The mechanisms of bupivacaine uncoupling have been extensively investigated.13,16,41–44
In a physiologic rat model of iterative exposure to local anesthetics, bupivacaine-induced myotoxicity is somewhat different, with a decrease in ATP synthesis accompanied by a reduction in the activity of all respiratory chain complexes I–IV and of citrate synthase activity.14,23
In the same way, iterative injections of bupivacaine could induce a decrease of mitochondrial content in muscles. Recent morphologic studies highlight the close link between ATP concentration and mitochondrial network organization.45,46
ATP deprivation leads to mitochondrial network fragmentation and can intervene early in the mediation of mitochondrial network reorganization. In our study, we could not access the mitochondrial network, but morphologic mitochondrial damages were observed in both bupivacaine groups coupled with ultrastructural muscle alterations. However, the muscle fibers exhibiting severe damage were exclusively seen in bupivacaine groups, suggesting that such severe lesions are drug dependent and that the hypothesis of mechanical fiber damage due to the applied fluid volume could be ruled out. Moreover, substantial quantitative differences in damaged fibers have been described when the toxic effects of bupivacaine and ropivacaine are compared on porcine skeletal muscle tissue.47
The lower toxic effects of ropivacaine compared with bupivacaine have also been described in human neuronal cells.48
Therefore, both the biochemical properties of local anesthetics and the age of the animals influence bupivacaine-induced myotoxicity.
Age-related differences in drug-induced mitochondrial bioenergetic toxicity in young tissue or cells, after bupivacaine exposure, have not been reported so far, whereas they have been after exposure to methylmercury.49
The latter induced strong inhibition both of state 3 mitochondrial respiration and ATP synthesis, with mitochondrial structural abnormalities characterized by disorganized cristae.50
Moreover, the toxic effects of methylmercury on mitochondrial function are age dependent,49
with greater decrease in mitochondrial metabolic function in young (postnatal day 21) rats than in adult (10- to 14-week-old) rats. In that study, the higher sensitivity of young rats to methylmercury contamination was attributed to lower basal activities in reactive oxygen species–detoxifying mechanisms. Such difference could also participate toward the stronger toxicity of bupivacaine in young individuals, because bupivacaine also triggers hydroxyl radical formation.51
Moreover, recent studies on the investigation of insulin resistance or statin-induced myotoxicity have shown a significant correlation between rodent and human muscle such that our results obtained on rats could have significance for humans.52,53
In the same way, bioenergetics (especially ATP synthesis) and reactive oxygen species–detoxifying mechanisms seem to be similar in rodent and human skeletal muscle.52,54
Furthermore, local anesthetic–induced myotoxicity could be overlooked clinically in children, and the rare case report does not mean that muscle pain and dysfunction do not happen. Our results highlight a larger toxicity in young rats, suggesting the lack of protective mechanisms, or the higher dependence of muscle on OXPHOS to produce energy. However, it can be proposed that (1) myotoxicity may well occur clinically in children but is not reported because of the difficulty of its detection or the absence of investigation; or (2) myotoxicity is characterized by a concentration-dependent effect, i.e.
, local anesthetic blocks in children have been performed with concentrations lower than 0.5%, potentially less toxic. Therefore, in the absence of supplemental data, clinical practice in children should not be changed, except that practitioners could be more vigilant regarding toxicity, particularly in situations where higher concentrations are needed to perform analgesia.
In conclusion, this study shows that iterative injections of bupivacaine induce a decrease in mitochondrial ATP synthesis and citrate synthase synthesis, suggesting a reduction of mitochondrial respiratory chain content, and muscle fibers exhibiting severe damages in rat. Moreover, young rats exhibit a higher rate of citrate synthase activity and ATP synthesis than adult rats. This study demonstrates that young age can enhance local anesthetic-induced myotoxicity. The clinical impact of our work remains to be evaluated in practice, and the need for a clinical evaluation of bupivacaine myotoxicity in young patients remains to be defined.
The authors thank Chantal Cazevieille, M.Sc. (Technician, Institut National de la Santé et de la Recherche Médicale ERI 25, Montpellier, France), for her technical assistance and for interpreting the data regarding ultrastructural evaluation. They also thank Françoise Masson, M.D. (Research Assistant, Pôle Anesthésie Réanimation, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France), for statistical support and Ray Cooke, Ph.D. (Assistant Research, Département des langues vivantes, Université Victor Segalen Bordeaux 2, Bordeaux, France), for proofreading the manuscript.
1. Ludot H, Berger J, Pichenot V, Belouadah M, Madi K, Malinovsky JM: Continuous peripheral nerve block for postoperative pain control at home: A prospective feasibility study in children. Reg Anesth Pain Med 2008; 33:52–6
2. Ganesh A, Rose JB, Wells L, Ganley T, Gurnaney H, Maxwell LG, DiMaggio T, Milovcich K, Scollon M, Feldman JM, Cucchiaro G: Continuous peripheral nerve blockade for inpatient and outpatient postoperative analgesia in children. Anesth Analg 2007; 105:1234–42
3. Ecoffey C: Pediatric regional anesthesia: Update. Curr Opin Anaesthesiol 2007; 20:232–5
4. Dadure C, Motais F, Ricard C, Raux O, Troncin R, Capdevila X: Continuous peripheral nerve blocks at home for treatment of recurrent complex regional pain syndrome I in children. Anesthesiology 2005; 102:387–91
5. Dadure C, Bringuier S, Nicolas F, Bromilow L, Raux O, Rochette A, Capdevila X: Continuous epidural block versus continuous popliteal nerve block for postoperative pain relief after major podiatric surgery in children: A prospective, comparative randomized study. Anesth Analg 2006; 102:744–9
6. Weintraud M, Marhofer P, Bosenberg A, Kapral S, Willschke H, Felfernig M, Kettner S: Ilioinguinal/iliohypogastric blocks in children: Where do we administer the local anesthetic without direct visualization? Anesth Analg 2008; 106:89–93
7. Cadera W: Diplopia after peribulbar anesthesia for cataract surgery. J Pediatr Ophthalmol Strabismus 1998; 35:240–1
8. Gunter JB: Benefit and risks of local anesthetics in infants and children. Paediatr Drugs 2002; 4:649–72
9. Gomez-Arnau JI, Yanguela J, Gonzalez A, Andres Y, Garcia del Valle S, Gili P, Fernandez-Guisasola J, Arias A: Anaesthesia-related diplopia after cataract surgery. Br J Anaesth 2003; 90:189–93
10. Rochette A, Dadure C, Raux O, Troncin R, Mailhee P, Capdevila X: A review of pediatric regional anesthesia practice during a 17-year period in a single institution. Paediatr Anaesth 2007; 17:874–80
11. Lacroix F: Epidemiology and morbidity of regional anaesthesia in children. Curr Opin Anaesthesiol 2008; 21:345–9
12. Rochette A, Dadure C, Raux O, Capdevila X: Changing trends in paediatric regional anaesthetic practice in recent years. Curr Opin Anaesthesiol 2009; 22:374–7
13. Irwin W, Fontaine E, Agnolucci L, Penzo D, Betto R, Bortolotto S, Reggiani C, Salviati G, Bernardi P: Bupivacaine myotoxicity is mediated by mitochondria. J Biol Chem 2002; 277:12221–7
14. Nouette-Gaulain K, Bellance N, Prevost B, Passerieux E, Pertuiset C, Galbes O, Smolkova K, Masson F, Miraux S, Delage JP, Letellier T, Rossignol R, Capdevila X, Sztark F: Erythropoietin protects against local anesthetic myotoxicity during continuous regional analgesia. Anesthesiology 2009; 110:648–59
15. Sztark F, Malgat M, Dabadie P, Mazat JP: Comparison of the effects of bupivacaine and ropivacaine on heart cell mitochondrial bioenergetics. Anesthesiology 1998; 88:1340–9
16. Sztark F, Nouette-Gaulain K, Malgat M, Dabadie P, Mazat JP: Absence of stereospecific effects of bupivacaine isomers on heart mitochondrial bioenergetics. Anesthesiology 2000; 93:456–62
17. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T: Mitochondrial threshold effects. Biochem J 2003; 370:751–62
18. Rossignol R, Letellier T, Malgat M, Rocher C, Mazat JP: Tissue variation in the control of oxidative phosphorylation: Implication for mitochondrial diseases. Biochem J 2000; 347(pt 1):45–53
19. Rossignol R, Malgat M, Mazat JP, Letellier T: Threshold effect and tissue specificity: Implication for mitochondrial cytopathies. J Biol Chem 1999; 274:33426–32
20. Benard G, Faustin B, Galinier A, Rocher C, Bellance N, Smolkova K, Casteilla L, Rossignol R, Letellier T: Functional dynamic compartmentalization of respiratory chain intermediate substrates: Implications for the control of energy production and mitochondrial diseases. Int J Biochem Cell Biol 2008; 40:1543–54
21. Faustin B, Rossignol R, Rocher C, Benard G, Malgat M, Letellier T: Mobilization of adenine nucleotide translocators as molecular bases of the biochemical threshold effect observed in mitochondrial diseases. J Biol Chem 2004; 279:20411–21
22. Greco M, Villani G, Mazzucchelli F, Bresolin N, Papa S, Attardi G: Marked aging-related decline in efficiency of oxidative phosphorylation in human skin fibroblasts. FASEB J 2003; 17:1706–8
23. Nouette-Gaulain K, Sirvent P, Canal-Raffin M, Morau D, Malgat M, Molimard M, Mercier J, Lacampagne A, Sztark F, Capdevila X: Effects of intermittent femoral nerve injections of bupivacaine, levobupivacaine, and ropivacaine on mitochondrial energy metabolism and intracellular calcium homeostasis in rat psoas muscle. Anesthesiology 2007; 106:1026–34
24. Veksler VI, Kuznetsov AV, Sharov VG, Kapelko VI, Saks VA: Mitochondrial respiratory parameters in cardiac tissue: A novel method of assessment by using saponin-skinned fibers. Biochim Biophys Acta 1987; 892:191–6
25. Letellier T, Malgat M, Coquet M, Moretto B, Parrot-Roulaud F, Mazat JP: Mitochondrial myopathy studies on permeabilized muscle fibers. Pediatr Res 1992; 32:17–22
26. Ouhabi R, Boue-Grabot M, Mazat JP: Mitochondrial ATP synthesis in permeabilized cells: Assessment of the ATP/O values in situ. Anal Biochem 1998; 263:169–75
27. Chance B, Williams G: Respiratory enzymes in oxidative phosphorylation. J Biol Chem 1955; 217:383–93
28. Lowry O, Rosebrough N, Farr A, Randall R: Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265–75
29. Srere P: Citrate synthase, Methods in Enzymology. Edited by Lowenstein J. New York, Academic Press, 1969, pp 3–11
30. Newham DJ, McPhail G, Mills KR, Edwards RH: Ultrastructural changes after concentric and eccentric contractions of human muscle. J Neurol Sci 1983; 61:109–22
31. Gibala MJ, MacDougall JD, Tarnopolsky MA, Stauber WT, Elorriaga A: Changes in human skeletal muscle ultrastructure and force production after acute resistance exercise. J Appl Physiol 1995; 78:702–8
32. Roth SM, Martel GF, Ivey FM, Lemmer JT, Tracy BL, Hurlbut DE, Metter EJ, Hurley BF, Rogers MA: Ultrastructural muscle damage in young versus older men after high-volume, heavy-resistance strength training. J Appl Physiol 1999; 86:1833–40
33. Hogan Q, Dotson R, Erickson S, Kettler R, Hogan K: Local anesthetic myotoxicity: A case and review. Anesthesiology 1994; 80:942–7
34. Padera R, Bellas E, Tse JY, Hao D, Kohane DS: Local myotoxicity from sustained release of bupivacaine from microparticles. Anesthesiology 2008; 108:921–8
35. Benard G, Faustin B, Passerieux E, Galinier A, Rocher C, Bellance N, Delage JP, Casteilla L, Letellier T, Rossignol R: Physiological diversity of mitochondrial oxidative phosphorylation. Am J Physiol Cell Physiol 2006; 291:C1172–82
36. Marcinek DJ, Schenkman KA, Ciesielski WA, Lee D, Conley KE: Reduced mitochondrial coupling in vivo alters cellular energetics in aged mouse skeletal muscle. J Physiol 2005; 569:467–73
37. Barazzoni R, Short KR, Nair KS: Effects of aging on mitochondrial DNA copy number and cytochrome c oxidase gene expression in rat skeletal muscle, liver, and heart. J Biol Chem 2000; 275:3343–7
38. Short KR, Bigelow ML, Kahl J, Singh R, Coenen-Schimke J, Raghavakaimal S, Nair KS: Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A 2005; 102:5618–23
39. Bortoli S, Renault V, Mariage-Samson R, Eveno E, Auffray C, Butler-Browne G, Pietu G: Modifications in the myogenic program induced by in vivo and in vitro aging. Gene 2005; 347:65–72
40. Kacser H, Burns JA: The control of flux. Symp Soc Exp Biol 1973; 27:65–104
41. Dabadie P, Bendriss P, Erny P, Mazat JP: Uncoupling effects of local anesthetics on rat liver mitochondria. FEBS Lett 1987; 226:77–82
42. Terada H, Shima O, Yoshida K, Shinohara Y: Effects of the local anesthetic bupivacaine on oxidative phosphorylation in mitochondria: Change from decoupling to uncoupling by formation of a leakage type ion pathway specific for H+ in cooperation with hydrophobic anions. J Biol Chem 1990; 265:7837–42
43. Schonfeld P, Sztark F, Slimani M, Dabadie P, Mazat JP: Is bupivacaine a decoupler, a protonophore or a proton-leak-inducer? FEBS Lett 1992; 304:273–6
44. Sun X, Garlid KD: On the mechanism by which bupivacaine conducts protons across the membranes of mitochondria and liposomes. J Biol Chem 1992; 267:19147–54
45. Benard G, Bellance N, James D, Parrone P, Fernandez H, Letellier T, Rossignol R: Mitochondrial bioenergetics and structural network organization. J Cell Sci 2007; 120:838–48
46. Benard G, Rossignol R: Ultrastructure of the mitochondrion and its bearing on function and bioenergetics. Antioxid Redox Signal 2008; 10:1313–42
47. Zink W, Seif C, Bohl JR, Hacke N, Braun PM, Sinner B, Martin E, Fink RH, Graf BM: The acute myotoxic effects of bupivacaine and ropivacaine after continuous peripheral nerve blockades. Anesth Analg 2003; 97:1173–9
48. Perez-Castro R, Patel S, Garavito-Aguilar ZV, Rosenberg A, Recio-Pinto E, Zhang J, Blanck TJ, Xu F: Cytotoxicity of local anesthetics in human neuronal cells. Anesth Analg 2009; 108:997–1007
49. Dreiem A, Gertz CC, Seegal RF: The effects of methylmercury on mitochondrial function and reactive oxygen species formation in rat striatal synaptosomes are age-dependent. Toxicol Sci 2005; 87:156–62
50. Cambier S, Benard G, Mesmer-Dudons N, Gonzalez P, Rossignol R, Brethes D, Bourdineaud JP: At environmental doses, dietary methylmercury inhibits mitochondrial energy metabolism in skeletal muscles of the zebra fish (Danio rerio). Int J Biochem Cell Biol 2009; 41:791–9
51. Wakata N, Sugimoto H, Iguchi H, Nomoto N, Kinoshita M: Bupivacaine hydrochloride induces muscle fiber necrosis and hydroxyl radical formation-dimethyl sulphoxide reduces hydroxyl radical formation. Neurochem Res 2001; 26:841–4
52. Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, Price JW III, Kang L, Rabinovitch PS, Szeto HH, Houmard JA, Cortright RN, Wasserman DH, Neufer PD: Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009; 119:573–81
53. Sirvent P, Mercier J, Vassort G, Lacampagne A: Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun 2005; 329:1067–75
54. Rasmussen UF, Vielwerth SE, Rasmussen HN: Skeletal muscle bioenergetics: A comparative study of mitochondria isolated from pigeon pectoralis, rat soleus, rat biceps brachii, pig biceps femoris and human quadriceps. Comp Biochem Physiol A Mol Integr Physiol 2004; 137:435–46
This article has been cited 3 time(s).
Patient Preference and AdherenceLiposomal extended-release bupivacaine for postsurgical analgesiaPatient Preference and Adherence
Journal of Shoulder and Elbow SurgeryRotator cuff healing after continuous subacromial bupivacaine infusion: an in vivo rabbit studyJournal of Shoulder and Elbow Surgery
Anesthesiology2009 in Review: Advancing Medicine in AnesthesiologyAnesthesiology
© 2009 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.